A biosynthetic antibody binding site, which incorporated the variable domains of anti-digoxin monoclonal antibody 26-10 in a single polypeptide chain (Mr = 26,354), was produced in Escherichia cofi by protein engineering. This variable region fragment (Fv) analogue comprised the 26-10 heavy-and light-chain variable regions (VH and VL) connected by a 15-amino acid linker to form a single-chain Fv (sFv). The sFv was designed as a prolyl-VH-(linker)-VL sequence of 248 amino acids. A 744-base-pair DNA sequence corresponding to this sFv protein was derived by using an E. colt codon preference, and the sFv gene was assembled starting from synthetic oligonucleotides. The sFv polypeptide was expressed as a fusion protein in E. colt, using a leader derived from the trp LE sequence. The sFv protein was obtained by acid cleavage of the unique Asp-Pro peptide bond engineered at the junction of leader and sFv in the fusion protein [(leader)-Asp-Pro-VH-(linker)-VL]. After isolation and renaturation, folded sFv displayed specificity for digoxin and related cardiac glycosides similar to that of natural 26-10 Fab fragments. Binding between afirmity-purified sFv and digoxin exhibited an association constant [Ka = (3.2 ± 0.9) x 107 M -1] that was about a factor of 6 smaller than that found for 26-10 Fab fragments [K. = (1.9 @ 0.2) x 108 M 'I under the same buffer conditions, consisting of 0.01 M sodium acetate, pH 5.5/0.25 M urea.It is known that antigen binding fragments of antibodies (1,2) can be refolded from denatured states with recovery of their specific binding activity (3)(4)(5)(6). The smallest such fragment that contains a complete binding site is termed Fv, consisting of an Mr 25,000 heterodimer of the VH and VL domains (2, 5-11). Givol and coworkers were the first to prepare an Fv by peptic digestion of murine IgA myeloma MOPC 315 (2). However, subsequent development of general cleavage procedures for Fv isolation has met with limited success (7-11). As a result, the Mr 50,000 Fab (1) has remained the only monovalent binding fragment used routinely in biomedical applications.An Fv analogue was constructed in which both heavy-and light-chain variable domains (VH and VL) were part of a single polypeptide chain. Synthetic genes for the 26-10 anti-digoxin VH and VL regions were designed to permit their connection through a linker segment, as well as other manipulations (12,13 MATERIALS AND METHODSModel Antibody. The digoxin binding site of the IgG2a,K monoclonal antibody 26-10 has been analyzed by MudgettHunter and colleagues (14-16). The 26-10 V region sequences were determined from both protein sequencing (17) (14) and has a well-defined specificity profile (15) (Fig. 1).Gene Synthesis. Design of the 744-base sequence for the synthetic sFv gene was derived from the sFv protein sequence by choosing codons preferred by E. coli (25). Synthetic genes encoding the trp promoter-operator, the modified trp LE leader peptide (MLE), and VH were prepared largely as described (26). The gene encoding VH was assembled from 46...

In an effort to extend automated Edman degradation to nanomole quantities of protein, the method of sequenator analysis described by Edman and Begg (Edman, P., and Begg, G. (1967), Eur. J. Biochem. 1, 80) was modified to permit long degradations in the absence of carrier proteins. By using an aqueous 0.1 M Quadrol program with limited, combined benezene-ethyl acetate solvent extractions, as well as a change in the delivery system for heptafluorobutyric acid, it was possible to recover and identify the first 30 amino acid residues from a sequenator run on 7 nmol of myoglobin. For 3 nmol of myoglobin, 20 steps could be identified. PTH-amino acids were identified by gas-liquid chromatography and thin-layer chromatography on polyamide sheets. Without using a carrier protein the cup to prevent mechanical losses (Niall, H. D., Jacobs, J. W., Van Rietshoten, J., and Tregear, G. W. (1974), FEBS Lett. 41, 62), the repetitive yield using this program was 93-96%. The same program has been applied successfully to peptides of 14 or more residues with or without modification by Braunitzer's reagent and to a number of larger peptides and proteins including a 216 residue segment of rabbit antibody heavy chain in which a sequence of 35 steps was accomplished on 25 nmol.

The results reviewed above reveal that during the anti-Ars immune response of strain A mice a somatic process that results in the evolution of V region structure occurs. This process involves both the selection of V regions encoded by particular gene segment combinations as well as the selection of structural variants of these V regions produced by somatic mutation as the immune response progresses. As a result, both quantitative and qualitative changes in the V region population initially elicited by immunization take place. The structural and functional character of the immune V region repertoire appears to be largely determined by this process of "somatic evolution" occurring in the primary response.

We have determined the three-dimensional structures of the antigen-binding fragment of the anti-digoxin monoclonal antibody 26-10 in the uncomplexed state at 2.7 A resolution and as a complex with digoxin at 2.5 A resolution.Neither the antibody nor digoxin undergoes any significant conformational changes upon forming the complex. Digoxin interacts primarily with the antibody heavy chain and is oriented such that the carbohydrate groups are exposed to solvent and the lactone ring is buried in a deep pocket at the bottom of the combining site. Despite extensive interactions between antibody and antigen, no hydrogen bonds or salt links are formed between 26-10 and digoxin. Thus the 26-10-digoxin complex is unique among the known three-dimensional structures ofantibody-antigen complexes in that specificity and high affinity arise primarily from shape complementarity.Digoxin (digoxigenin tridigitoxoside; Structure I) inhibits the Na+,K+-ATPase and is used in treatment of congestive heart failure (1). Digoxin is a cardenolide-type steroid with an a,4-unsaturated lactone ring attached at C-17 and three P(1 -+ 4)-D-glycoside-linked digitoxoses attached at 0-3. It is a relatively large and rigid hapten, whose internal degrees of freedom are limited to rotations about the lactone-cardenolide bond (C-17 to C-20; Structure Anti-digoxin antibodies have been used to measure serum digoxin levels as a guide to therapy and to treat otherwise fatal digoxin intoxication (3). Anti-digoxin antibodies complexed with structurally distinct digoxin congeners are also an excellent model system to study the structural basis of antibody specificity.The antibody 26-10 (IgG2a, K light chain) is a murine monoclonal antibody that exhibits high affinity (1010 M-1) for digoxin and varying specificity for digoxin congeners (4-6). Both the intact 26-10 antibody and the 26-10 Fab (antigenbinding fragment) reverse lethal digoxin toxicity in guinea pigs (7). Spontaneous and site-directed mutants of26-10 have been generated (6,8,9). The specificities of 26-10 and its mutants have been characterized for a wide range of digoxin congeners (6, 8, 9).We report the three-dimensional structures of the 26-10 Fab fragment at 2.7 A resolution and of the Fab-digoxin complex at 2.5 A resolution.i ¶ MATERIALS AND METHODS Antibody 26-10 was obtained from A/J mice immunized with a digoxin-human serum albumin conjugate (4). Purified antibody was cleaved by papain, and the Fab was purified by using ion-exchange chromatography (10). Crystals of the 26-10 Fab-digoxin complex were grown in the presence of a 3-fold molar excess of digoxin from 16% to 18% (wt/wt) polyethylene glycol (average Mr = 8000) with 1.7% (vol/vol) 2-methyl-2,4-pentanediol in 10 mM sodium phosphate at pH 7.5 (11